NASDAQ · Financial Statements

Pacira BioSciences, Inc. (PCRX) Financial Statements

$36.42 NASDAQ: PCRX Market Cap $1.45B

Pacira BioSciences, Inc. most recently reported annual revenue of $726.0M, net profit of $7.0M. Revenue grew at an average annual rate of 11.0% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Pacira BioSciences, Inc.: Revenue rose from $276.0M in 2016 to $726.0M in 2025, a change of +163.0% over 9 years; net profit was positive in 5 of 10 reported years; operating margin moved from -11.6% to 4.6%, a shift of +16.2 percentage points; the most recent year shows net profit of $7.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$276.0M$287.0M$337.0M$421.0M$430.0M$542.0M$667.0M$675.0M$701.0M$726.0M
Operating Expenses$308.0M$312.0M$321.0M$411.0M$383.0M$452.0M$607.0M$587.0M$774.0M$693.0M
Operating Profit$-32.0M$-25.0M$16.0M$10.0M$46.0M$90.0M$60.0M$88.0M$-73.0M$33.0M
Operating Margin-11.6%-8.7%4.7%2.5%10.8%16.6%9.0%13.0%-10.5%4.6%
Other Income$-6.0M$-18.0M$-16.0M$-21.0M$-26.0M$-34.0M$-47.0M$-26.0M$10.0M$-16.0M
Interest$7.0M$18.0M$22.0M$24.0M$26.0M$29.0M$36.0M$17.0M$17.0M$15.0M
Depreciation$13.0M$14.0M$13.0M$20.0M$20.0M$29.0M$92.0M$76.0M$79.0M$91.0M
Profit Before Tax$-38.0M$-42.0M$0$-11.0M$20.0M$56.0M$13.0M$62.0M$-63.0M$17.0M
Tax$-280,000$-330,000$-10.8M$-2.5M$-624.4M$25.6M$-19.6M$32.0M$-57.8M$58.3M
Net Profit$-38.0M$-43.0M$0$-11.0M$146.0M$42.0M$16.0M$42.0M$-100.0M$7.0M
EPS$-1.02$-1.07$-0.01$-0.27$3.33$0.92$0.34$0.89$-2.15$0.16
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$164.0M$181.0M$167.0M$178.0M$169.0M$187.0M$169.0M$181.0M$180.0M$197.0M$177.0M$192.0M
Operating Expenses$146.0M$148.0M$154.0M$150.0M$308.0M$163.0M$167.0M$173.0M$173.0M$194.0M$173.0M$188.0M
Operating Profit$18.0M$33.0M$13.0M$28.0M$-140.0M$25.0M$2.0M$8.0M$6.0M$3.0M$5.0M$4.0M
Operating Margin10.8%18.3%7.9%15.9%-82.8%13.2%1.2%4.7%3.5%1.6%2.6%2.2%
Interest$3.0M$3.0M$3.0M$3.0M$5.0M$4.0M$5.0M$5.0M$4.0M$3.0M$3.0M$4.0M
Profit Before Tax$17.0M$34.0M$14.0M$37.0M$-139.0M$26.0M$9.0M$-2.0M$10.0M$1.0M$5.0M$3.0M
Tax$34.6M$26.3M$34.2M$48.4M$-3.3M$37.2M$44.7M$-151.5M$43.0M$-186.7M$41.7M$-82.1M
Net Profit$11.0M$25.0M$9.0M$19.0M$-143.0M$16.0M$5.0M$-5.0M$5.0M$2.0M$3.0M$5.0M
EPS$0.23$0.48$0.19$0.39$-3.11$0.34$0.10$-0.11$0.12$0.04$0.07$0.12

Over the 10 years reported for Pacira BioSciences, Inc., borrowings increased from $109.0M in 2016 to $454.0M in 2025, cash stood at $159.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 4.53 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$391.0M$628.0M$689.0M$831.0M$1.3B$2.1B$1.7B$1.6B$1.6B$1.3B
Current Assets$243.0M$391.0M$478.0M$409.0M$652.0M$866.0M$498.0M$510.0M$745.0M$548.0M
Cash$36.0M$54.0M$133.0M$78.0M$100.0M$586.0M$104.0M$153.0M$277.0M$159.0M
Inventory$31.0M$41.0M$49.0M$58.0M$65.0M$99.0M$96.0M$104.0M$125.0M$153.0M
Receivables$30.0M$32.0M$38.0M$48.0M$53.0M$96.0M$98.0M$106.0M$113.0M$124.0M
Fixed Assets$101.0M$107.0M$109.0M$143.0M$211.0M$265.0M$254.0M$235.0M$216.0M$182.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$137.0M$331.0M$291.0M$279.0M$517.0M$71.0M$222.0M$128.0M$237.0M$80.0M
Other Assets$47.0M$55.0M$62.0M$100.0M$100.0M$145.0M$163.0M$163.0M$0$20.0M
Total Liabilities$172.0M$349.0M$368.0M$476.0M$655.0M$1.3B$906.0M$704.0M$775.0M$572.0M
Current Liabilities$45.0M$56.0M$61.0M$108.0M$253.0M$521.0M$148.0M$97.0M$310.0M$121.0M
Borrowings$109.0M$276.0M$291.0M$352.0M$541.0M$1.1B$763.0M$586.0M$639.0M$454.0M
Other Liabilities$64.0M$72.0M$77.0M$124.0M$114.0M$216.0M$143.0M$118.0M$136.0M$117.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$219.0M$279.0M$321.0M$355.0M$620.0M$730.0M$775.0M$870.0M$778.0M$693.0M

For Pacira BioSciences, Inc., operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $137.0M; free cash flow was positive in 9 of 10 years; financing activities used $154.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$33.0M$18.0M$49.0M$71.0M$77.0M$126.0M$145.0M$155.0M$189.0M$152.0M
Investing Cash Flow$-86.0M$-243.0M$6.0M$-139.0M$-315.0M$-67.0M$-255.0M$62.0M$-94.0M$84.0M
Financing Cash Flow$7.0M$-3.0M$9.0M$4.0M$30.0M$-10.0M$-1.0M$-2.0M$-59.0M$-154.0M
Net Cash Flow$-21.0M$18.0M$78.0M$-54.0M$22.0M$486.0M$-481.0M$49.0M$123.0M$-118.0M
Free Cash Flow$9.0M$-1.0M$34.0M$60.0M$39.0M$80.0M$115.0M$139.0M$179.0M$137.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.10
EV / EBITDA10.38
FCF Yield18.22%
Quick Ratio3.94
Interest Coverage1.33
Return 1Y16.54%
Return 3Y-29.63%
Return 5Y-55.40%

Pacira BioSciences, Inc. (PCRX) financials — frequently asked questions

What is Pacira BioSciences, Inc.'s annual revenue?

Pacira BioSciences, Inc. (PCRX) reported annual revenue of $726.0M in its most recent fiscal year.

What is Pacira BioSciences, Inc.'s net profit?

Pacira BioSciences, Inc. (PCRX) reported net profit of $7.0M in its most recent fiscal year.

What is PCRX EV/EBITDA?

Pacira BioSciences, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 10.38.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
PCRX Overview PCRX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.